Literature DB >> 12733594

Antiprothrombin antibodies are associated with pregnancy loss in patients with the antiphospholipid syndrome.

P von Landenberg1, T Matthias, J Zaech, M Schultz, M Lorber, M Blank, Y Shoenfeld.   

Abstract

OBJECTIVE: To document the clinical association between the history of pregnancy loss in patients with the diagnosis of primary or secondary antiphospholipid syndrome (APS) and the presence of different antiprothrombin antibody subtypes [immunoglobulin G (IgG), IgM and IgA] in a cohort of patients with APS.
METHODS: Records of 170 female patients with primary APS, or APS secondary to systemic lupus erythematosus (SLE) or secondary to other autoimmune diseases were studied.
RESULTS: In female APS patients with IgG antiprothrombin antibodies (n = 105) significant associations to pregnancy loss (p < 0.0001), early pregnancy loss (p < 0.0001) and a negative association to thrombocytopenia (p < 0.01) could be identified. In the group of patients with IgG antiprothrombin antibodies and at least one pregnancy (n = 84) a significant association with pregnancy loss (p < 0.005) and especially with early pregnancy loss (p < 0.0001) was demonstrated. No association with other immunoglobulin subtypes of antiprothrombin antibodies could be documented. In the subgroup of patients with primary APS and at least one pregnancy in the history, pregnancy loss (p < 0.005) and early pregnancy loss (p < 0.0001) were found to be highly associated with the presence of IgG antiprothrombin antibodies. IgG antiprothrombin antibodies represent the highest independent risk factor for pregnancy loss with an odds ratio of 4.5. There was no statistically significant association with venous or arterial thrombosis in all IgG antiprothrombin antibody positive patients.
CONCLUSION: The results of this study document the association of IgG antiprothrombin antibodies with pregnancy loss and in particular early pregnancy loss in a large and well-characterized cohort of patients. We would recommend routine testing for antiprothrombin antibodies in young female patients with APS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12733594     DOI: 10.1034/j.1600-0897.2003.01153.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  6 in total

Review 1.  Autoimmunity and recurrent pregnancy losses.

Authors:  Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

2.  Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?

Authors:  Francesca Pregnolato; Cecilia B Chighizola; Susan Encabo; Zakera Shums; Gary L Norman; Armando Tripodi; Veena Chantarangkul; Tiziana Bertero; Valeria De Micheli; Maria Orietta Borghi; Pier Luigi Meroni
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

3.  Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay.

Authors:  M Sénant; H Rostane; F Fernani-Oukil; F Hosking; F Bellery; A Courchinoux; E Tartour; L Darnige; M-A Dragon-Durey
Journal:  J Immunol Res       Date:  2015-05-06       Impact factor: 4.818

4.  Bouquet variety of antiphospholipid antibodies in recurrent pregnancy loss.

Authors:  Marta P Baleva; Zhivka P Karagyozova; Milena K Nikolova-Vlahova; Krasimir V Nikolov; Petar K Nikolov
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

5.  Detection of non-criteria autoantibodies in women without apparent causes for pregnancy loss.

Authors:  Hongyuan Zhu; Meng Wang; Ying Dong; Honghai Hu; Qiaoli Zhang; Chen Qiao; Xin Xie; Fei Fan; Jiazi Zeng; Yan Jia; Lu Chen; Jingrui Liu; Lin Li; Yanhong Zhai; Zhen Zhao; Min Shen; Zheng Cao
Journal:  J Clin Lab Anal       Date:  2019-08-11       Impact factor: 2.352

Review 6.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.